Cargando…

Utility of adjuvant whole abdominal radiation therapy in ovarian clear cell cancer (OCCC): a pragmatic cohort study of women with classic immuno-phenotypic signature

BACKGROUND: To evaluate the initial experience and clinical utility of first-line adjuvant intensity-modulated whole abdominal radiation therapy (WART) in women with ovarian clear cell cancer (OCCC) referred to an academic center. METHODS: Progression-free and overall survival was analyzed in a prag...

Descripción completa

Detalles Bibliográficos
Autores principales: Stevens, Mark J., West, Simon, Gard, Gregory, Renaud, Christopher, Nevell, David, Roderick, Stephanie, Le, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7866446/
https://www.ncbi.nlm.nih.gov/pubmed/33549120
http://dx.doi.org/10.1186/s13014-021-01750-4
_version_ 1783648078002126848
author Stevens, Mark J.
West, Simon
Gard, Gregory
Renaud, Christopher
Nevell, David
Roderick, Stephanie
Le, Andrew
author_facet Stevens, Mark J.
West, Simon
Gard, Gregory
Renaud, Christopher
Nevell, David
Roderick, Stephanie
Le, Andrew
author_sort Stevens, Mark J.
collection PubMed
description BACKGROUND: To evaluate the initial experience and clinical utility of first-line adjuvant intensity-modulated whole abdominal radiation therapy (WART) in women with ovarian clear cell cancer (OCCC) referred to an academic center. METHODS: Progression-free and overall survival was analyzed in a pragmatic observational cohort study of histologically pure OCCC patients over-expressing HNF-1ß treated between 2013 and end-December 2018. An in-house intensity-modulated WART program was developed from a published pre-clinical model. Radiation dose-volume data was curated to American Association of Physics in Medicine (AAPM) Task Group 263 recommendations. A dedicated database prospectively recorded presenting characteristics and outcomes in a standardized fashion. RESULTS: Five women with FIGO (2018) stage IA to IIIA2 OCCC were treated with first-line WART. Median age was 58 years (range 47–68 years). At diagnosis CA-125 was elevated in 4 cases (median 56 kU/L: range 18.4–370 kU/L) before primary de-bulking surgery. Severe premorbid endometriosis was documented in 3 patients. At a median follow-up of 77 months (range 16–83 mo.), all patients remain alive and progression-free on clinical, biochemical (CA-125), and (18)Fluoro-deoxyglucose (FDG) PET/CT re-evaluation. Late radiation toxicity was significant (G3) in 1 case who required a limited bowel resection and chronic nutritional support at 9 months post-WART; 2 further patients had asymptomatic (G2) osteoporotic fragility fractures of axial skeleton at 12 months post-radiation treated with anti-resorptive agents (denosumab). CONCLUSIONS: The clinical utility of intensity-modulated WART in OCCC over-expressing HNF-1β was suggested in this small observational cohort study. The hypothesis that HNF-1β is a portent of platinum-resistance and an important predictive biomarker in OCCC needs further confirmation. Curating multi-institutional cohort studies utilizing WART by means of “Big Data” may improve OCCC care standards in the future.
format Online
Article
Text
id pubmed-7866446
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-78664462021-02-08 Utility of adjuvant whole abdominal radiation therapy in ovarian clear cell cancer (OCCC): a pragmatic cohort study of women with classic immuno-phenotypic signature Stevens, Mark J. West, Simon Gard, Gregory Renaud, Christopher Nevell, David Roderick, Stephanie Le, Andrew Radiat Oncol Research BACKGROUND: To evaluate the initial experience and clinical utility of first-line adjuvant intensity-modulated whole abdominal radiation therapy (WART) in women with ovarian clear cell cancer (OCCC) referred to an academic center. METHODS: Progression-free and overall survival was analyzed in a pragmatic observational cohort study of histologically pure OCCC patients over-expressing HNF-1ß treated between 2013 and end-December 2018. An in-house intensity-modulated WART program was developed from a published pre-clinical model. Radiation dose-volume data was curated to American Association of Physics in Medicine (AAPM) Task Group 263 recommendations. A dedicated database prospectively recorded presenting characteristics and outcomes in a standardized fashion. RESULTS: Five women with FIGO (2018) stage IA to IIIA2 OCCC were treated with first-line WART. Median age was 58 years (range 47–68 years). At diagnosis CA-125 was elevated in 4 cases (median 56 kU/L: range 18.4–370 kU/L) before primary de-bulking surgery. Severe premorbid endometriosis was documented in 3 patients. At a median follow-up of 77 months (range 16–83 mo.), all patients remain alive and progression-free on clinical, biochemical (CA-125), and (18)Fluoro-deoxyglucose (FDG) PET/CT re-evaluation. Late radiation toxicity was significant (G3) in 1 case who required a limited bowel resection and chronic nutritional support at 9 months post-WART; 2 further patients had asymptomatic (G2) osteoporotic fragility fractures of axial skeleton at 12 months post-radiation treated with anti-resorptive agents (denosumab). CONCLUSIONS: The clinical utility of intensity-modulated WART in OCCC over-expressing HNF-1β was suggested in this small observational cohort study. The hypothesis that HNF-1β is a portent of platinum-resistance and an important predictive biomarker in OCCC needs further confirmation. Curating multi-institutional cohort studies utilizing WART by means of “Big Data” may improve OCCC care standards in the future. BioMed Central 2021-02-06 /pmc/articles/PMC7866446/ /pubmed/33549120 http://dx.doi.org/10.1186/s13014-021-01750-4 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Stevens, Mark J.
West, Simon
Gard, Gregory
Renaud, Christopher
Nevell, David
Roderick, Stephanie
Le, Andrew
Utility of adjuvant whole abdominal radiation therapy in ovarian clear cell cancer (OCCC): a pragmatic cohort study of women with classic immuno-phenotypic signature
title Utility of adjuvant whole abdominal radiation therapy in ovarian clear cell cancer (OCCC): a pragmatic cohort study of women with classic immuno-phenotypic signature
title_full Utility of adjuvant whole abdominal radiation therapy in ovarian clear cell cancer (OCCC): a pragmatic cohort study of women with classic immuno-phenotypic signature
title_fullStr Utility of adjuvant whole abdominal radiation therapy in ovarian clear cell cancer (OCCC): a pragmatic cohort study of women with classic immuno-phenotypic signature
title_full_unstemmed Utility of adjuvant whole abdominal radiation therapy in ovarian clear cell cancer (OCCC): a pragmatic cohort study of women with classic immuno-phenotypic signature
title_short Utility of adjuvant whole abdominal radiation therapy in ovarian clear cell cancer (OCCC): a pragmatic cohort study of women with classic immuno-phenotypic signature
title_sort utility of adjuvant whole abdominal radiation therapy in ovarian clear cell cancer (occc): a pragmatic cohort study of women with classic immuno-phenotypic signature
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7866446/
https://www.ncbi.nlm.nih.gov/pubmed/33549120
http://dx.doi.org/10.1186/s13014-021-01750-4
work_keys_str_mv AT stevensmarkj utilityofadjuvantwholeabdominalradiationtherapyinovarianclearcellcancerocccapragmaticcohortstudyofwomenwithclassicimmunophenotypicsignature
AT westsimon utilityofadjuvantwholeabdominalradiationtherapyinovarianclearcellcancerocccapragmaticcohortstudyofwomenwithclassicimmunophenotypicsignature
AT gardgregory utilityofadjuvantwholeabdominalradiationtherapyinovarianclearcellcancerocccapragmaticcohortstudyofwomenwithclassicimmunophenotypicsignature
AT renaudchristopher utilityofadjuvantwholeabdominalradiationtherapyinovarianclearcellcancerocccapragmaticcohortstudyofwomenwithclassicimmunophenotypicsignature
AT nevelldavid utilityofadjuvantwholeabdominalradiationtherapyinovarianclearcellcancerocccapragmaticcohortstudyofwomenwithclassicimmunophenotypicsignature
AT roderickstephanie utilityofadjuvantwholeabdominalradiationtherapyinovarianclearcellcancerocccapragmaticcohortstudyofwomenwithclassicimmunophenotypicsignature
AT leandrew utilityofadjuvantwholeabdominalradiationtherapyinovarianclearcellcancerocccapragmaticcohortstudyofwomenwithclassicimmunophenotypicsignature